ARDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
ARDELYX, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.09+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $766.53M
- P/E (TTM)
- –
- Dividend yield
- –
ARDELYX, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $118.13M | $93.37M | $114.40M | $105.52M | $90.08M | $67.81M | $111.00M | $92.09M | $72.59M | $43.51M | $30.58M | $22.29M | 97.7% | +31.1% |
| IBSRELA | $86.24M | $70.07M | $86.60M | $78.16M | $65.05M | $44.40M | $53.84M | $40.64M | $35.45M | $28.36M | $28.11M | $22.29M | 71.3% | +32.6% |
| XPHOZAH | $31.89M | $23.30M | $27.80M | $27.36M | $25.03M | $23.41M | $57.16M | $51.45M | $37.15M | $15.15M | $2.46M | $0 | 26.4% | +27.4% |
| Product supply revenue | $1.98M | $354.00K | $9.44M | $0 | $6.19M | $254.00K | $4.19M | $5.32M | $13.00K | $2.13M | $767.00K | $2.09M | 1.6% | -68.1% |
| Non-cash royalty revenue related to the sale of future royalties | $676.00K | $695.00K | $1.35M | $4.79M | $1.38M | $1.03M | $916.00K | $809.00K | $599.00K | $368.00K | $0 | $0 | 0.6% | -51.0% |
| Licensing revenue | $96.00K | $51.00K | $23.00K | $25.00K | $20.00K | $5.02M | $22.00K | $20.00K | $19.00K | $17.00K | $3.02M | $32.01M | 0.1% | +380.0% |
By region
From the segment and revenue-disaggregation notes of Ardelyx's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.